Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study
ConclusionsAnalysis of the effect of OP therapies on hip geometry is useful in understanding the mechanisms of their anti-fracture effect and may provide additional information on their efficacy. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - January 9, 2024 Category: Endocrinology Source Type: research
Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis
CONCLUSIONS: Denosumab use reduces the risk of RA in patients with osteoporosis. Receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclast joint damage may be involved in the pathogenesis of RA during the preclinical stage.PMID:38179713 | DOI:10.55563/clinexprheumatol/3ohsj3 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - January 5, 2024 Category: Rheumatology Authors: Chun-Hsiung Chen Hsien-Tzung Liao Hung-An Chen Yi-Ning Yen Chen-Hung Chen Source Type: research
Atypical femur fracture in a male without history of bisphosphonate use: a case report
ConclusionsThis case underscores the significance of considering atypical femur fractures in older individuals with limited trauma history. It accentuates the role of anabolic agents in the therapeutic regimen and contributes to the evolving understanding of atypical femur fractures. The report underscores the need for vigilant monitoring and tailored management strategies in similar cases, thereby enhancing clinical practice and patient care. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - January 4, 2024 Category: General Medicine Source Type: research
Falsely elevated parathyroid hormone in a patient with osteoporosis: a case report and review
We report a case of falsely high PTH levels due to assay interference and review the literature on cases of spuriously elevated PTH.Case reportAn 87-year-old woman attending our bone health clinic with osteoporosis had persistently elevated PTH (383 –784 pg/ml) using the Roche Cobas e801 immunoassay despite having normal serum calcium, phosphate, 25 hydroxyvitamin D (> 50 nmol/l) and eGFR (> 60 ml/min). To rule out falsely elevated PTH, a polyethylene glycol precipitation (PEG) test was performed which recovered less than 10% of the hormone resulting in a normal level. PTH was also tested on a different a...
Source: Osteoporosis International - December 28, 2023 Category: Orthopaedics Source Type: research
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature
Expert Opin Pharmacother. 2023 Dec 15. doi: 10.1080/14656566.2023.2296543. Online ahead of print.ABSTRACTINTRODUCTION: Osteoporosis, which is characterized by compromised bone density and heightened susceptibility to fractures, is a substantial public health concern, especially among the aging population. Underdiagnosis, undertreatment, and therapy non-adherence contribute to its impact. Anabolic and dual-action agents like teriparatide, abaloparatide, and romosozumab have emerged as effective treatments, allowing rapid gains in bone mineral density (BMD) and reducing fracture risk. However, administering treatments in the...
Source: Expert Opinion on Pharmacotherapy - December 15, 2023 Category: Drugs & Pharmacology Authors: Ilaria Mondo Sophia Hannou Patrizia D'Amelio Source Type: research
Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study
ConclusionThis large-scale, multicenter chart review provides clinically relevant insights into the profiles of patients initiating romosozumab, effectiveness of real-world romosozumab use, and sequential therapy in Japanese patients at high risk of fracture. (Source: Journal of Bone and Mineral Metabolism)
Source: Journal of Bone and Mineral Metabolism - December 12, 2023 Category: Orthopaedics Source Type: research
The Fracture Incidence and Safety of Teriparatide and Bisphosphonate in Postmenopausal Women With Osteoporosis: A Meta-Analysis
CONCLUSIONS: Among postmenopausal women with osteoporosis, clinical vertebral fractures and new vertebral fractures decreased more in patients receiving teriparatide than in those receiving bisphosphonate. Although there were no differences in adverse events across subgroups, patients receiving teriparatide had a higher rate of dizziness than those receiving bisphosphonate.The results of this work will provide a reference for clinicians to select appropriate anti-osteoporosis drugs by comprehensively considering individual differences such as fracture risk and dizziness tolerance.PMID:38064598 (Source: Alternative Therapie...
Source: Alternative Therapies in Health and Medicine - December 8, 2023 Category: Complementary Medicine Authors: Qi Zhong Yuanyue Liao Wen Zou Source Type: research
The Fracture Incidence and Safety of Teriparatide and Bisphosphonate in Postmenopausal Women With Osteoporosis: A Meta-Analysis
CONCLUSIONS: Among postmenopausal women with osteoporosis, clinical vertebral fractures and new vertebral fractures decreased more in patients receiving teriparatide than in those receiving bisphosphonate. Although there were no differences in adverse events across subgroups, patients receiving teriparatide had a higher rate of dizziness than those receiving bisphosphonate.The results of this work will provide a reference for clinicians to select appropriate anti-osteoporosis drugs by comprehensively considering individual differences such as fracture risk and dizziness tolerance.PMID:38064598 (Source: Alternative Therapie...
Source: Alternative Therapies in Health and Medicine - December 8, 2023 Category: Complementary Medicine Authors: Qi Zhong Yuanyue Liao Wen Zou Source Type: research
